Join the club for FREE to access the whole archive and other member benefits.

Racing for the lead... Underdog becomes Cyclarity Therapeutics


Key points from article :

Cyclarity is now the brand under which the team will strive to cure heart disease and to make its mark in the field of aging.

The company has realised that in the race to cure atherosclerosis, it has become rather hard to refer to itself as the underdog.

Michael Kope, CEO and Co-founder, explained to Longevity.Technology that the "brand that both refers to our core technology, and suggests to our partners a long-term vision for the future of the treatment of age-related diseases.”

The biotech remains on track to commence human clinical trials for UDP-003 in 2023.

Cyclarity Therapeutics has just completed the move of its research and operations to the state-of-the-art labs at the Buck Institute for Research on Aging.

Will offer access to core facilities and an opportunity to expand its relationships with many world leaders in cardiovascular disease and the field of aging.

Also announces move to Buck Institute for Research on Aging

Mentioned in this article:

Click on resource name for more details.

Buck Institute

Independent biomedical research institute focused on aging

Cyclarity Therapeutics

Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases.

Michael Kope

Co-Chief Executive Officer and Co-founder Underdog Pharmaceuticals